Eton Pharma Initiates Pilot Study for ET-700 in Wilson Disease, Targets $100M+ Peak Sales
Summary
Eton Pharmaceuticals has begun a pilot clinical study for ET-700, an extended-release zinc acetate formulation for Wilson disease, with results expected in H2 2026 and potential peak sales exceeding $100 million.
Key Events
-
Clinical Study Initiated for ET-700
Eton Pharmaceuticals has dosed the first patient in a pilot clinical study for ET-700, an extended-release zinc acetate formulation for Wilson disease.
-
Significant Market Potential
The CEO projects ET-700 could achieve over $100 million in peak annual sales in the United States if approved, representing a substantial revenue opportunity.
-
Study Design and Timeline
The double-blinded, placebo-controlled study involves 36 healthy volunteers, comparing ET-700 to Galzin® and a placebo. Topline results are anticipated in the second half of 2026, with a pivotal study planned for early 2027 if results are positive.
-
Addressing Patient Needs
The study aims to explore a simpler, more convenient dosing approach for the lifelong treatment of Wilson disease, potentially improving patient adherence.
Analysis
This filing signals a significant step forward in Eton Pharmaceuticals' product pipeline, as it initiates a pilot clinical study for ET-700, a potential new treatment for Wilson disease. The CEO's projection of over $100 million in peak annual sales highlights the material revenue opportunity this candidate represents for the company. While this is an early-stage pilot study, its successful progression could significantly enhance the company's long-term growth prospects and address an unmet need for a more convenient dosing regimen in Wilson disease treatment. Investors should monitor the upcoming topline results in the second half of 2026 for further updates on this program.
At the time of this filing, ETON was trading at $23.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $628.1M. The 52-week trading range was $13.09 to $27.29. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.